


NYC RYAN WHITE PART A CARE COORDINATION & THE CHORDS STUDY*

Stephanie Chamberlin, MIA, MPH
Care and Treatment Unit
Bureau of HIV/AIDS Prevention and Control
New York City Department of Health and Mental Hygiene

*CHORDS is supported through a grant from NIMH (1R01MH101028).



CHORDS is a
research
partnership of:

New York City
Department of
Health and
Mental
Hygiene, New
York, NY

&

CUNY School of
Public Health,
New York, NY

BACKGROUND: NYC RYAN WHITE PART A CCP

CCP Goal:

Ensure that **HIV+ Ryan White clients** at risk for **suboptimal health outcomes** receive support to achieve full **engagement in care and treatment** through coordinated care strategies

CCP INTERVENTION DESCRIPTION

- **CCP model provides:**
 - case management
 - patient navigation, including accompaniment
 - adherence support, including directly observed therapy (DOT)
 - health promotion in home visits
 - assistance with medical/social services
- See CDC Compendium of Evidence-based Interventions:
http://www.cdc.gov/hiv/pdf/prevention/research/compendium/cdc-hiv-HIVCCP_EI_Retention.pdf


CARE COORDINATION PROGRAM (CCP) POPULATION

- **Eligibility based on indicators of need:**
 - newly diagnosed;
 - previously lost to care/never in care;
 - irregularly in care;
 - initiating a new regimen; and/or
 - showing incomplete medication adherence or response to treatment.

CCP Lead and Partner Service Sites, 2015^a


- ☆ Lead CCP Service Site
- Partner CCP Service Site

HIV Prevalence as % of UHF^b Population, 2013



^a For multi-site programs, all sites are displayed in the same color.

^b The United Hospital Fund (UHF) classifies NYC into 42 neighborhoods, comprising contiguous zip codes.



28 CCP
AGENCIES IN
NYC



STUDY AIMS




- **Aim 1**: *To assess short and long-term CCP effectiveness by comparing care engagement and VL suppression among CCP participants with those of similar PLWH in HIV care who do not receive the CCP intervention.*

METHODS


**Aim 1: Pre-
Post Study**

DATA SOURCES

- Matched CCP programmatic data with NYC HIV Registry data



STUDY ELIGIBILITY



STATISTICAL MEASURES

■ Outcome Measures:

- Engagement in Care (EiC): ≥ 2 CD4 or VL tests ≥ 90 days apart, with ≥ 1 in each half of 12-month period
 - Viral Load Suppression (VLS): $VL \leq 200$ copies/mL on most recent test in second half of 12-month period*
- Estimated post- vs. pre- CCP enrollment relative risks (RRs) for EiC and VLS using GEE

*Missing VL in 2nd half of 12-month period considered equivalent to unsuppressed VL.

PSYCHOSOCIAL BARRIERS

Psychosocial Barriers (Definitions)*

- **Unstable housing:** Homelessness or residence in temporary/transitional housing
- **Lower mental health functioning:** Mental component summary (MCS) score ≤ 37.0 on the SF-12(v2) functional health assessment
- **Recent hard drug use:** Self-report of using heroin, cocaine, methamphetamines, or Rx drugs to get high (past 3 months)

* Based on CCP Assessment: Baseline = Intake Assessment;
Post-baseline=Reassessment

PSYCHOSOCIAL BARRIER REDUCTION

Reduction of Psychosocial Barriers (Definitions)*


- **Housing barrier reduction:** If unstable housing present at baseline, evidence of stable housing post-baseline
- **Mental health barrier reduction:** If MCS ≤ 37.0 at baseline, a post-baseline MCS score increase ≥ 3.5 points
- **Drug-related barrier reduction:** If recent hard drug use present at baseline, no use of these drugs post-baseline

* Based on latest CCP Assessment during the year of follow-up


RESULTS

**Aim 1:
Pre-Post
Study**


ENGAGEMENT IN CARE, PRE & POST




VL SUPPRESSION, PRE & POST




POST- VS. PRE- ENROLLMENT CHANGE, RELATIVE RISK BY LENGTH OF CCP ENROLLMENT (PREVIOUSLY DX'D)




PSYCHOSOCIAL BARRIER PREVALENCE: PREVIOUSLY DX'D



ENGAGEMENT IN CARE: POST- VS. PRE-ENROLLMENT (RR, 95% CI)



VIRAL LOAD SUPPRESSION: POST- VS. PRE-ENROLLMENT (RR, 95% CI)




PROPORTION OF THOSE WITH BARRIER AT BASELINE WHO SUBSEQUENTLY EXPERIENCED BARRIER REDUCTION


POST-BASELINE BARRIER REDUCTION %



EIC BY BARRIER REDUCTION: POST- VS. PRE-ENROLLMENT (RR, 95% CI)



VLS BY BARRIER REDUCTION: POST- VS. PRE-ENROLLMENT (RR, 95% CI)



PRELIMINARY COMPARISON GROUP WORK

**Aim 1:
Comparison
Group**

CHORDS COMPARISON GROUP ANALYSIS: CCP EFFECTIVENESS

■ Comparison Group Aim:

- To compare care engagement and VL suppression among CCP participants with those of similar PLWH in HIV care who do not receive the CCP intervention.

■ Why?:

- To control for patterns (e.g. upward trends) in care engagement and VL suppression that may occur independently of the CCP intervention.
- EiC and VLS have been steadily improving in NYC overall, so some amount of improvement in any one program should not surprise us.

METHODS: COMPARISON GROUP

Step 1: Select base comparison group of similar non-CCP enrollees from all PLWH in NYC, to include those PLWH who:

- Had at least 1 CD4/VL reported to surveillance December 2007 – March 2013
- Met CCP eligibility anytime between December 2009 and March 2013
- Were not enrolled in the CCP before March 2014

Step 2: Assign each non-CCP PLWH a ‘pseudo enrollment date’ (aka ‘anchor date’) that:

- Results in a set of anchor dates fitting the CCP enrollment date distribution (by enrollment month)

Step 3: Perform propensity score matching to identify those PLWH were:


- Most similar to CCP participants with regard to many measured factors

REVISED STATISTICAL MEASURES


■ Outcome Measures:

- Engagement in Care (EiC): ≥ 2 CD4 or VL tests ≥ 90 days apart *in the 12-month period*
- Viral Load Suppression (VLS): VL ≤ 200 copies/mL on most recent test *in the 12-month period**
- Estimated CCP vs. non-CCP relative risks (RRs) for EiC/VLS (at 12-month follow-up) using GEE
- Stratified outcomes to compare groups with same baseline EiC/VLS (or newly Dx'd) status

*Missing VL *in the 12-month period* considered equivalent to unsuppressed VL.




PRELIMINARY DATA: CARE ENGAGEMENT AT 12-MONTH FOLLOW-UP (%) - CCP VERSUS NON-CCP, BY BASELINE STATUS



EIC - Engagement in Care status at baseline
 VLS - Viral Load Suppression status at baseline

PRELIMINARY DATA: VIRAL SUPPRESSION AT 12-MONTH FOLLOW-UP (%) - CCP VERSUS NON-CCP, BY BASELINE STATUS



EIC - Engagement in Care status at baseline
VLS - Viral Load Suppression status at baseline

DISCUSSION

CONCLUSIONS (PRE-POST ANALYSES)

- **Significant EiC/VLS increases occurred in all subgroups examined, including those with key barriers to HIV care and treatment adherence**
- **Findings suggest a link between support to reduce psychosocial barriers and greater improvement on 12-month EiC/VLS outcomes**
- **CCP shows promise for increasing health/survival opportunities among those at highest risk for suboptimal HIV health outcomes**

CONCLUSIONS (COMPARISON GROUP ANALYSES)

- In short-term (12-mo.) comparisons of CCP clients' post-enrollment EiC and VLS to the EiC and VLS achieved among other, similar PLWH:
 - The CCP demonstrates effectiveness at increasing EiC and VLS overall (above and beyond the increases among similar PLWH in 'usual care' over the same period)
 - Benefits of the CCP appear less substantial for individuals who were already engaged in care at the time of CCP enrollment.
- Evidence of CCP effectiveness over usual care suggests the public health value of intervention scale-up, focusing on PLWH with the greatest need, lowest engagement in care



STUDY AIMS



- **Aim 1**: *To assess short and long-term CCP effectiveness by comparing care engagement and VL suppression among CCP participants with those of similar PLWH in HIV care who do not receive the CCP intervention.*
- **Aim 2**: *Among those who enroll in the CCP, identify individual and CCP site-level determinants of care engagement and VL suppression up to 36 months following CCP enrollment.*
- **Aim 3**: *To assess the cost-effectiveness (cost per quality-adjusted life year [QALY]) of the CCP relative to usual care outside the CCP, considering downstream cost-savings and individual and public health benefits due to improved VL suppression and HIV infections averted.*